维普期刊资源整合服务平台（V6.5）

66篇 您的检索式：作者名="Van Cutsem G"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Definition and classification of power system stability 显示文摘	KUNDUR P PASERBA J AJJARAPU V ANDERSSON G BOSE A CANIZARES C HATZIARGYRIOU N HILL D STANKOVICA TAYLOR C van CUTSEM T VITTAL V	2004	IEEE Transactions on Power Systems2004，19，3：	1
2	Treatment response and mor- tality among patients starting antiretroviral therapy with and without ka- posi sarcoma : a cohort study 显示文摘	Maskew M Fox MP Van Cutsem G	2013	PLoS One2013，8，64：	1
3	Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone显示文摘	van Cutsem E Rutgeerts P Vantrappen G		Lancet0，，：	1
4	KRAS status and efficacy in the firstline treatment of patient with metastatic coloreetal caneer (mCRC) treated with FOLFIRI with or without eetuximab: The CRYSTAL experience 显示文摘	Van Cutsem E Lang L D haens G	2008	J Clin Oneol2008，，：	1
5	KRAS status and efficacy in the first -line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience 显示文摘	Van Cutsem E Lang I D' haens G Moiseyenko V Zaluski J Fol- precht G	2008	J Gin Oncol2008，2620，2：	1
6	Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone显示文摘	van Cutsem E Rutgeerts P Vantrappen G	1990	Lancet1990，335，8695：	1
7	KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer(mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience 显示文摘	Van Cutsem E Lang I D'haens G	2008	J Clin Oncol2008，26，15：	1
8	K-RAS status and efficacy in the first-line treatment ofpatients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience显示文摘	Van CUTSEM E LANG I DHAENS G	2008	J Clin Oncol2008，26，15：	1
9	Open, ran- domized, multicentertrial of raltitrexed versus fluorouracil plus high-dose leucovorinin patients with advanced colorec- tal cancer显示文摘	Cocconi G Cunningham D Van Cutsem E	1998	J Clin Oncol1998，16，9：	1
10	Analysis of blood plasma factors in the AVITA Phase III randomized study of bevacizumab (bey) with gemcitabine - erlotinib ( GE ) in pa- tients(pts ) with metastatic pancreatic cancer (mPC) 显示文摘	Van Cutsem E Jayson G Dive C	2011	European Muhidisciplinary Cancer Congress Stockholm2011，，9：	1
11	KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience 显示文摘	Van Cutsem E Lang I D'haens G	2008	J Clin Oncol2008，26，：	1
12	KRAS status and efficacy in the first- line treatment of patients with metastatic colorectal cancer(mCRC) treated with FOLFI- RI with or without cetuximab:the CRYSTAL experience 显示文摘	Van Cutsem E Lang I Dr Haens G	2008	J Clin Oncolo2008，26，1：	1
13	Model predictive control of voltages in active distribution networks显示文摘	Valverde G Van Cutsem T	2013	IEEE Transactions on Smart Grid2013，4，4：	1
14	Chicory seed-lot variety identification by leucine-aminopeptidase and esterase zymogram analysis显示文摘	Baes P G Van Cutsem P J	1992	E - lectr_ophoresis1992，13，：	1
15	Treatment of bleeding gastrointestinal vascular malfor-Mations with oestrogen-progesterone显示文摘	VAN CUTSEM E RUTGEERTS P VANTRAPPEN G	1990	Lancet1990，335，：	1
16	KRAS status and efficacy in the first- line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIR1 with or without cetuximab: The CRYSTAL experlence显示文摘	Van Cutsem E Lang L Dhaens G	2005	J Clin Oncol2005，，：	1
17	ENETS Consensus Guidelines for the management of patients with gas- troduodenal neoplasms 显示文摘	Delle Fave G Kwekkeboom DJ Van Cutsem E	2012	Neuroendocrinology2012，95，2：	1
18	K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIR1 with or without cetuximab : the CRYTAL experience 显示文摘	VAN CUTSEM E LANG I DHAENS G	2008	J Clin Oncol2008，26，：	1
19	KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab:The CRYSTAL experience显示文摘	Van Cutsem E Lang I D' haens G	2008	Proc Am Soc Clin Oncol2008，26，20：	1
20	K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYTAL experience 显示文摘	Van Cutseme Lang I Dhaens G	2008	J Clin Oncol2008，26，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示